KANDLELIT-013NCT07431827
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 31 versions: 28 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 120 → 125 locations
- Minor Study sites: 120 to 122
- Minor Trial sites expanded: 115 → 120 locations
- Minor Study sites: 115 to 117
- Minor Trial sites expanded: 110 → 115 locations
- Minor Study sites: 110 to 112
- Minor Trial sites expanded: 106 → 110 locations
- Notable Eligibility criteria expanded, about 20 words
- Trial sites expanded: 101 → 106 locations
- Secondary endpoints: details revised at 2 of 11 entries
- Minor Trial sites expanded: 95 → 101 locationsv22
- Minor Trial sites expanded: 86 → 95 locationsv21
- Minor Trial sites expanded: 82 → 86 locationsv20
- Minor Trial sites expanded: 79 → 82 locationsv18
- Minor Trial sites expanded: 72 → 79 locationsv17
- Minor Trial sites expanded: 69 → 72 locationsv16
- Minor Trial sites expanded: 65 → 69 locationsv15
- Minor Trial sites expanded: 59 → 65 locationsv14
- Minor Study sites: 58 to 59v13
- Minor Study sites: 56 to 58v12
- Minor Trial sites expanded: 49 → 56 locationsv11
- Minor Trial sites expanded: 36 → 49 locationsv10
- Minor Trial sites expanded: 24 → 36 locationsv9
- Minor Trial sites expanded: 17 → 24 locationsv8
- Minor Study sites: 16 to 17v7
- Minor Study sites: 14 to 16v6
- Minor Trial sites expanded: 1 → 14 locationsv5
- Minor Interventions: MK-1084 (Drug), MK-3475A (Biological), Placebo (Drug) to Calderasib (Drug), MK-3475A (Biological), Placebo (Drug)
- Study title expanded, about 1 word
- Notable Recruitment opened
- Study sites: 0 to 1
- Start date changed from estimate of Apr 1, 2026 to Mar 18, 2026
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Disease-free Survival (DFS)
Timeframe: Up to ~11 years
Secondary (11)
Overall Survival (OS)
Distant Metastasis-Free Survival (DMFS)
Lung Cancer Specific Survival (LCSS)
Change from Baseline in the European Organization for Research and Treatment of Cancer (EORTC)-Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score
Change from Baseline in the EORTC-QLQ-C30 Physical Functioning (Items 1-5) Combined Score
Show 6 moreShow less
Change from Baseline in the EORTC-QLQ-C30 Role Functioning (Items 6 and 7) Combined Score
Change from Baseline in the EORTC-QLQ-C30 Dyspnea (Item 8) Score
Change from Baseline in the EORTC-Quality of Life Questionnaire-Lung Cancer 24 (QLQ-LC24) Coughing (Items 31 and 52) Combined Score
Change from Baseline in the EORTC-QLQ-LC24 Chest Pain (Item 40) Score
Number of Participants Who Experience an Adverse Event (AE)
Number of Participants Who Discontinue Study Treatment Due to an AE
Arms and interventions
Calderasib + MK-3475AExperimental
Participants receive calderasib daily (qd) and MK-3475A every 6 weeks (q6w) for up to 9 doses.
Placebo + MK-3475AActive comparator
Participants receive placebo qd and MK-3475A q6w for up to 9 doses.
Drugs: Calderasib, Placebo
Biologicals: MK-3475A
Sites
125 sites in 19 countries
China 27, Ukraine 15, Turkey (Türkiye) 11, Spain 9, Brazil 8, Japan 7, Greece 6, Colombia 5, South Korea 5, Taiwan 5, Argentina 4, Chile 4, France 4, Australia 3, Canada 3, Hong Kong 3, Italy 3, United Kingdom 2, Poland 1